ChromaDex Corporation (NASDAQ:CDXC), might not be a large cap stock, but it saw significant share price movement during recent months on the NASDAQCM, rising to highs of US$10.54 and falling to the lows of US$7.29. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether ChromaDex's current trading price of US$7.29 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at ChromaDex’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.
View our latest analysis for ChromaDex
What's the opportunity in ChromaDex?
Great news for investors – ChromaDex is still trading at a fairly cheap price. According to my valuation, the intrinsic value for the stock is $11.99, but it is currently trading at US$7.29 on the share market, meaning that there is still an opportunity to buy now. What’s more interesting is that, ChromaDex’s share price is quite volatile, which gives us more chances to buy since the share price could sink lower (or rise higher) in the future. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.
What kind of growth will ChromaDex generate?
Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to grow by 32% over the next year, the near-term future seems bright for ChromaDex. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.
What this means for you:
Are you a shareholder? Since CDXC is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation.
Are you a potential investor? If you’ve been keeping an eye on CDXC for a while, now might be the time to make a leap. Its prosperous future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy CDXC. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed investment decision.
If you want to dive deeper into ChromaDex, you'd also look into what risks it is currently facing. You'd be interested to know, that we found 2 warning signs for ChromaDex and you'll want to know about them.
If you are no longer interested in ChromaDex, you can use our free platform to see our list of over 50 other stocks with a high growth potential.
If you decide to trade ChromaDex, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted
Valuation is complex, but we're here to simplify it.
Discover if Niagen Bioscience might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisThis article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
About NasdaqCM:NAGE
Niagen Bioscience
Operates as a bioscience company engages in developing healthy aging products.
Flawless balance sheet with reasonable growth potential.
Similar Companies
Market Insights
Community Narratives

